Evalución [sic] de la densidad mineral ósea en la monitorización de la mujer menopáusica en tratamiento hormonal sustitutivo de una área de Barcelona

Introduction: The osteoporosis was defined in the year 1993 as a systemic squeleton disease caraterized by a reduced bonemass and a bone tissue microarquitecture deterioration. The reduced bone mass is a typical anomaly of osteoporosis. The other anomaly observed is the derangement of normal microar...

Full description

Bibliographic Details
Author: Checa, Miguel Angel|||0000-0002-0226-3416
Format: doctoral thesis
Publication Date:2004
Country:España
Institution:Universitat Autònoma de Barcelona
Repository:Dipòsit Digital de Documents de la UAB
Language:Spanish
OAI Identifier:oai:ddd.uab.cat:37634
Online Access:https://ddd.uab.cat/record/37634
Access Level:Open access
Keyword:Densitometria òssia
Menopausa
Osteoporosi
id ES_a041cfec13be5bdb0d10bb027c6cb5f3
oai_identifier_str oai:ddd.uab.cat:37634
network_acronym_str ES
network_name_str España
repository_id_str
spelling Evalución [sic] de la densidad mineral ósea en la monitorización de la mujer menopáusica en tratamiento hormonal sustitutivo de una área de BarcelonaCheca, Miguel Angel|||0000-0002-0226-3416Densitometria òssiaMenopausaOsteoporosiIntroduction: The osteoporosis was defined in the year 1993 as a systemic squeleton disease caraterized by a reduced bonemass and a bone tissue microarquitecture deterioration. The reduced bone mass is a typical anomaly of osteoporosis. The other anomaly observed is the derangement of normal microarchitecture petter. There is a less number of bone trabeculae in the osteoporotic bone and the trabecules are thiner than regular ones; there are as well horizontal backups that are not linked with other structures and therefore they do not give any structural support.The doble source energy radiologic densitometry (DEXA) is the gold standard for the bone mass measurement. The transdermic hormonal replacement therapy prevents bonemass loss. Objectives: Main: Estimation of the needed interval between two densitometries so real differences show up between two consecutive densitometries. Secondary: Evaluation of recognizable risk factors for bone mass loss between two consecutive densitometries, stablish differences when progesterone is added and economic cost assesement. Pacients and Methods: Prospective cohort study in which 3826 postmenopausal patients where included and entered the inclusion criteria, to whom a densitometry was made within the period of January 1994 and December1995. A control group of 2393 patients, a group which received transdermical strogens of 807 patients and a group which received Strogens and progesterone of 626 patients. All where folowed up for a maximun period of 5 years being made an annul DEXA. Results: Lumbar bone L1-L4. Treatment with strogens OR: 0.472 IC95% (0.389-0.572); Age > 55 years OR: 0.618 IC95% (0.534-0.715); Body Mass Index OR: 0.604 IC95% (0.525-0.694) Menopause>45 años OR: 1.300 IC95% (1.118-1.511). Osteopenia in basal DEXA OR: 1.879 IC95% (1.575-2.242); normal in DEXA OR: 2.553 IC95% (2.100-3.105). 1-2 years period from basal DEXA No significative. 2-3 years period from basal DEXA No significative. 3-4 years period OR 1.869 IC95% (1.420-2460). 4-5 years period OR: 2.164 IC95% (1.492-3.138). Conclusions: DEXA can be done to patients who are under hormonal replacement therapy in periods no shorter than 3 years. Except for the high risk patients, body mass index < 25 or age below 55 years.Universitat Autònoma de BarcelonaCarreras Collado, Ramón 22004-01-0120042004-01-01Tesi doctoralhttp://purl.org/coar/resource_type/c_db06VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/doctoralThesisapplication/pdfhttps://ddd.uab.cat/record/37634reponame:Dipòsit Digital de Documents de la UABinstname:Universitat Autònoma de BarcelonaEspañolspaopen accesshttp://purl.org/coar/access_right/c_abf2Aquest material està protegit per drets d'autor i/o drets afins. Podeu utilitzar aquest material en funció del que permet la legislació de drets d'autor i drets afins d'aplicació al vostre cas. Per a d'altres usos heu d'obtenir permís del(s) titular(s) de drets.https://rightsstatements.org/vocab/InC/1.0/info:eu-repo/semantics/openAccessoai:ddd.uab.cat:376342026-06-06T12:50:31Z
dc.title.none.fl_str_mv Evalución [sic] de la densidad mineral ósea en la monitorización de la mujer menopáusica en tratamiento hormonal sustitutivo de una área de Barcelona
title Evalución [sic] de la densidad mineral ósea en la monitorización de la mujer menopáusica en tratamiento hormonal sustitutivo de una área de Barcelona
spellingShingle Evalución [sic] de la densidad mineral ósea en la monitorización de la mujer menopáusica en tratamiento hormonal sustitutivo de una área de Barcelona
Checa, Miguel Angel|||0000-0002-0226-3416
Densitometria òssia
Menopausa
Osteoporosi
title_short Evalución [sic] de la densidad mineral ósea en la monitorización de la mujer menopáusica en tratamiento hormonal sustitutivo de una área de Barcelona
title_full Evalución [sic] de la densidad mineral ósea en la monitorización de la mujer menopáusica en tratamiento hormonal sustitutivo de una área de Barcelona
title_fullStr Evalución [sic] de la densidad mineral ósea en la monitorización de la mujer menopáusica en tratamiento hormonal sustitutivo de una área de Barcelona
title_full_unstemmed Evalución [sic] de la densidad mineral ósea en la monitorización de la mujer menopáusica en tratamiento hormonal sustitutivo de una área de Barcelona
title_sort Evalución [sic] de la densidad mineral ósea en la monitorización de la mujer menopáusica en tratamiento hormonal sustitutivo de una área de Barcelona
dc.creator.none.fl_str_mv Checa, Miguel Angel|||0000-0002-0226-3416
author Checa, Miguel Angel|||0000-0002-0226-3416
author_facet Checa, Miguel Angel|||0000-0002-0226-3416
author_role author
dc.contributor.none.fl_str_mv Carreras Collado, Ramón
dc.subject.none.fl_str_mv Densitometria òssia
Menopausa
Osteoporosi
topic Densitometria òssia
Menopausa
Osteoporosi
description Introduction: The osteoporosis was defined in the year 1993 as a systemic squeleton disease caraterized by a reduced bonemass and a bone tissue microarquitecture deterioration. The reduced bone mass is a typical anomaly of osteoporosis. The other anomaly observed is the derangement of normal microarchitecture petter. There is a less number of bone trabeculae in the osteoporotic bone and the trabecules are thiner than regular ones; there are as well horizontal backups that are not linked with other structures and therefore they do not give any structural support.The doble source energy radiologic densitometry (DEXA) is the gold standard for the bone mass measurement. The transdermic hormonal replacement therapy prevents bonemass loss. Objectives: Main: Estimation of the needed interval between two densitometries so real differences show up between two consecutive densitometries. Secondary: Evaluation of recognizable risk factors for bone mass loss between two consecutive densitometries, stablish differences when progesterone is added and economic cost assesement. Pacients and Methods: Prospective cohort study in which 3826 postmenopausal patients where included and entered the inclusion criteria, to whom a densitometry was made within the period of January 1994 and December1995. A control group of 2393 patients, a group which received transdermical strogens of 807 patients and a group which received Strogens and progesterone of 626 patients. All where folowed up for a maximun period of 5 years being made an annul DEXA. Results: Lumbar bone L1-L4. Treatment with strogens OR: 0.472 IC95% (0.389-0.572); Age > 55 years OR: 0.618 IC95% (0.534-0.715); Body Mass Index OR: 0.604 IC95% (0.525-0.694) Menopause>45 años OR: 1.300 IC95% (1.118-1.511). Osteopenia in basal DEXA OR: 1.879 IC95% (1.575-2.242); normal in DEXA OR: 2.553 IC95% (2.100-3.105). 1-2 years period from basal DEXA No significative. 2-3 years period from basal DEXA No significative. 3-4 years period OR 1.869 IC95% (1.420-2460). 4-5 years period OR: 2.164 IC95% (1.492-3.138). Conclusions: DEXA can be done to patients who are under hormonal replacement therapy in periods no shorter than 3 years. Except for the high risk patients, body mass index < 25 or age below 55 years.
publishDate 2004
dc.date.none.fl_str_mv 2
2004-01-01
2004
2004-01-01
dc.type.none.fl_str_mv Tesi doctoral
http://purl.org/coar/resource_type/c_db06
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/doctoralThesis
format doctoralThesis
dc.identifier.none.fl_str_mv https://ddd.uab.cat/record/37634
url https://ddd.uab.cat/record/37634
dc.language.none.fl_str_mv Español
spa
language_invalid_str_mv Español
language spa
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://rightsstatements.org/vocab/InC/1.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://rightsstatements.org/vocab/InC/1.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Universitat Autònoma de Barcelona
publisher.none.fl_str_mv Universitat Autònoma de Barcelona
dc.source.none.fl_str_mv reponame:Dipòsit Digital de Documents de la UAB
instname:Universitat Autònoma de Barcelona
instname_str Universitat Autònoma de Barcelona
reponame_str Dipòsit Digital de Documents de la UAB
collection Dipòsit Digital de Documents de la UAB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869414995805077504
score 15,300719

Similar Items